Genmab — Januar 2018
-
Bouschka (BerGenBio) – Intersting approach to tackle EGFR resistance not driven by T790M, Axl is a very intriguing target but still not validated. So far data are not very compelling, I would hope to see objective responses if Axl is truly a primary resistance switch. I like the trial design, though, wish more IO drugs (e.g. NKTR) would be evaluated that way…
Ohad
-
-
God morgen.
-
God morgen
-
As nice as this sounds, it isn't really correct, is it? : "For the first time, an approach to target different cell groups within single tumors based on their respective characteristics has been developed by the scientists from Netherlands Cancer Institute in Amsterdam, in collaboration with the biotechnology company Genmab A/S" http://www.biovoicenews.com/personalized-cancer-treatment-2-0-new-combination-strategy-developed/
-
When did Winkel say we could
expect first AXL data? 2018 or 2019? -
OHW - nu ved vi jo at analytikere ikke vil tillægge prekliniske data nogen synderlig værdi! Så almindelig anerkendt er det først i deres verden når der er resultater fra klinikken
-
As of December 2016, there were at least eight other compounds in clinical or preclinical development that target AXL or its ligand....etc https://www.biocentury.com/bc-extra/preclinical-news/2018-01-15/combination-therapy-could-treat-tumors-resistant-mapk-pathway-?kwh="HuMax-AXL-ADC"
-
AXL kan blive en rigtig gamechanger. Genmab ejer 100%, SGEN skal have single digit royalties, som kan udvikle sig til double digit.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind